Palvella Therapeutics Inc. Company Profile
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics at a glance
Palvella Therapeutics Inc. (NASDAQ: PVLA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Wayne, PA. Palvella Therapeutics is led by Mr. Wesley H. Kaupinen and employs about 29 people. At a market capitalization of $1.88 billion, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001583648, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Palvella Therapeutics do?
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Palvella Therapeutics Inc.
- Ticker
- NASDAQ: PVLA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Wesley H. Kaupinen
- Employees
- 29
- Headquarters
- 353 W. Lancaster Avenue, Wayne, PA, United States
- Phone
- 484 253 1461
- Website
- palvellatx.com
- Market cap
- $1.88B
- SEC CIK
- 0001583648
- Latest annual report
- 10-K · Mar 31, 2026
Companies similar to Palvella Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ADRXADARx Pharmaceuticals Inc. | 17.68 | +1.99% | $1.89B | vs PVLA |
| XERSXeris Biopharma Holdings Inc. | 10.19 | +0.79% | $1.86B | vs PVLA |
| AGIOAgios Pharmaceuticals Inc. | 31.92 | +0.41% | $1.91B | vs PVLA |
| SRPTSarepta Therapeutics Inc. | 18.21 | +4.06% | $1.92B | vs PVLA |
| LKFTLakefront Biotherapeutics ADR | 29.51 | -1.63% | $1.93B | vs PVLA |
| GPCRStructure Therapeutics Inc. ADR | 25.67 | -3.79% | $1.83B | vs PVLA |
| TRVITrevi Therapeutics Inc. | 12.83 | -2.40% | $1.83B | vs PVLA |
| XNCRXencor Inc. | 24.50 | +0.99% | $1.82B | vs PVLA |